J&J | JNJ - Sales Revenues


J&J reported $24.1B in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
AbbVie USD 15B 1.62B Mar/2026
Abbott USD 11.16B 300M Mar/2026
Amgen USD 8.62B 1.28B Mar/2026
AstraZeneca USD 15.29B 213M Mar/2026
Baxter International USD 2.7B 270M Mar/2026
Bayer EUR 13.41B 1.97B Mar/2026
Becton, Dickinson and Co. USD 4.7B 600M Mar/2026
Biogen USD 2.25B 30M Mar/2026
Boston Scientific USD 5.2B 90M Mar/2026
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
CONMED USD 317M 56.2M Mar/2026
Cooper Companies USD 1.08B 57.4M Mar/2026
Dexcom USD 1.19B 70M Mar/2026
Edwards Lifesciences USD 1.65B 80M Mar/2026
Eli Lilly USD 19.8B 500M Mar/2026
Gilead Sciences USD 7B 930M Mar/2026
GlaxoSmithKline GBP 7.63B 991M Mar/2026
Globus Medical USD 759.85M 66.55M Mar/2026
Insulet USD 761.7M 22.1M Mar/2026
Integra LifeSciences USD 391.9M 43M Mar/2026
Intuitive Surgical USD 2.77B 100M Mar/2026
J&J USD 24.1B 500M Mar/2026
Medtronic USD 9.8B 800M Mar/2026
Merck USD 16.29B 110M Mar/2026
Merit Medical Systems USD 381.9M 12M Mar/2026
Novartis USD 13.11B 226M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
Regeneron Pharmaceuticals USD 3.6B 280M Mar/2026
Roche Holding CHF 15.65B 274.5M Dec/2025
Sanofi EUR 11.24B 60M Mar/2026
Stryker USD 6B 1.2B Mar/2026
Tandem Diabetes Care USD 247.22M 43.18M Mar/2026
Teva Pharmaceutical Industries USD 11.77B 2.86B Mar/2026
Vertex Pharmaceuticals USD 2.99B 200M Mar/2026
Zimmer Biomet Holdings USD 2.09B 150M Mar/2026
Zoetis USD 2.3B 100M Mar/2026